Liminatus Pharma Short Crowding Reached 181.80% of Real Float
The biotech's real-float short crowding rose 107.29 percentage points versus the prior FINRA settlement.
Coverage: 10 of 2998 companies in this theme (SEZL, MRSH, DOCS, SATL, NRXP, VIVK, GYRE, WLFC, EBS, LIMN) — a sample, not the full set.
Liminatus Pharma, Inc. (LIMN) recorded 181.80% of real float short on the FINRA settlement date of 2026-08-14, a 107.29 percentage-point increase versus the 2026-07-31 settlement.
The biotech's crowding was computed from 10,331,073 shares short divided by 44,877,633 shares outstanding, multiplied by a 0.1266 size-index free-float factor. That settlement-to-settlement move was the largest among the names in this cycle.
NRX Pharmaceuticals, Inc. (NRXP) also built crowding, reaching 216.53% of real float short, up 52.95 percentage points from the prior settlement. Emergent BioSolutions Inc. (EBS) rose 25.45 percentage points to 183.83% of real float short. Satellogic Inc. (SATL) added 12.55 percentage points to reach 229.07%. Sezzle Inc. (SEZL) rose 9.56 percentage points to 249.74%.
Gyre Therapeutics, Inc. (GYRE) shed 8.96 percentage points of crowding, ending at 201.02% of real float short. Willis Lease Finance Corp. (WLFC) declined 14.59 percentage points to 191.96%. MARSH & MCLENNAN COMPANIES, INC. (MRSH) sat at 247.06% of real float short, and Doximity, Inc. (DOCS) at 239.50%, with no prior-settlement comparison supplied. Vivakor, Inc. (VIVK) ranked at 201.73%.
Sezzle remained the most crowded name in the set at 249.74% of real float short. Liminatus Pharma's 107.29-point jump was the sharpest settlement-to-settlement move among the names listed.